Merck beats Q1 profit forecast but pipeline needs to fill in for Singulair expiry
This article was originally published in Scrip
Executive Summary
Merck & Co's first-quarter earnings narrowly beat analyst expectations, as the company continued to cut costs and saw solid sales of blockbuster asthma therapy Singulair (montelukast) and good contributions from its diabetes franchise.